🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 89 of 151

  1. OPDIVO 10 mg/mL concentrate for solution for infusion., JNJ-63723283, Zr89

    Disc Medicine

    Patients with metastatic solid tumours, where clinical data has shown a rationale for ICI therapy.

    phase 2 small molecule active

    1 trial

  2. OPDIVO 10 mg/mL concentrate for solution for infusion., Kymriah 1.2 x 10^6 – 6 x 10^8 cells dispersion for infusion

    Pari Pharma GmbH

    children, adolescents and young adults with Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  3. OPDIVO 10 mg/mL concentrate for solution for infusion., Mektovi 15 mg film-coated tablets, YERVOY 5 mg/ml concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, Braftovi 75 mg hard capsules

    Ningbo Cancer Hospital

    BRAF V600 mutation–positive unresectable or metastatic melanoma

    phase 2 small molecule active

    1 trial

  4. OPDIVO 10 mg/mL concentrate for solution for infusion., Regorafenib_IJB

    The George Institute

    Locally-advanced stage II-III rectal cancer

    phase 2 small molecule active

    1 trial

  5. OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab intravenous

    The George Institute

    Adult participants with advanced unresectable or metastatic soft-tissue sarcoma.

    phase 2 small molecule active

    1 trial

  6. OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab intravenous, 0.9% Sodium Chloride Injection, Avastin 25 mg/ml concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced/metastatic hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  7. OPDIVO 10 mg/mL concentrate for solution for infusion., Stivarga 40 mg film-coated tablets, anti-CTLA-4 NF Probody® mAb

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), urothelial carcinoma, gastric, esophageal, cervical, and colorectal cancer (CRC)).

    phase 2 small molecule active

    1 trial

  8. OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion

    Ningbo Cancer Hospital

    NEOREM: Localized solid malignancies that are eligible to receive neo-adjuvant therapy and have medical unmet needs related to disease-free survival, overall survival or quality of life / NEO-1: Resectable stage III cutaneous or mucosal melanoma amenable to intratumoral neo-adjuvant immunotherapy.

    phase 2 small molecule active

    1 trial

  9. OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion

    Tour Hekla

    Unresectable locally advanced or metastatic urothelial cancer

    phase 2 small molecule active

    1 trial

  10. OPM-101

    Chongqing Precision Biotech Co., Ltd

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  11. OPRX-106

    Protalix BioTherapeutics

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  12. ORIC-114

    Topiloric/Uriadec

    Solid Tumors

    phase 2 small molecule active

    1 trial

  13. ORIC-114

    Topiloric/Uriadec

    Solid Tumors

    phase 2 small molecule active

    1 trial

  14. ORKA-001

    Oruka Therapeutics

    Plaque Psoriasis

    phase 2 small molecule active

    2 trials

  15. ORKA-001 Induction Dose

    Oruka Therapeutics

    Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  16. ORKA-001, Placebo for ORKA-001

    Oruka Therapeutics

    Moderate-to-Severe Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  17. ORKA-002

    Oruka Therapeutics

    Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  18. ORMD 0801

    ORAMED PHARMACEUTICALS INC.

    Brittle Type I Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  19. ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    Diabetes Type 2

    phase 2 small molecule completed

    1 trial

  20. ORMD-0801 (Insulin) capsule 8 mg BD

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  21. ORMD-0801 Capsules

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus Type 1

    phase 2 mab completed

    1 trial

  22. ORMD-0801 Dose # 1

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus Type 2

    phase 2 small molecule completed

    1 trial

  23. ORMD-0801 QD

    ORAMED PHARMACEUTICALS INC.

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  24. ORMD-0801 Treatment A

    ORAMED PHARMACEUTICALS INC.

    Type 1 Diabetes

    phase 2 small molecule completed

    1 trial

  25. ORMD-0801 capsules- 2x8mg

    ORAMED PHARMACEUTICALS INC.

    Type 1 Diabetes

    phase 2 small molecule completed

    1 trial

  26. ORSERDU 86 mg film-coated tablets, ABEMACICLIB, ABEMACICLIB, ORSERDU 345 mg film-coated tablets, ABEMACICLIB

    Stemline Therapeutics B.V.

    Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  27. ORSERDU 86 mg film-coated tablets, LETROZOLE , -, ORSERDU 345 mg film-coated tablets, Kisqali 200 mg film-coated tablets, EXEMESTANE , ANASTROZOLE

    Shanghai Reinovax Biologics Co.,LTD

    endocrine-responsive HER2-negative early breast cancer

    phase 2 small molecule active

    1 trial

  28. ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets

    Stemline Therapeutics B.V.

    metastatic breast cancer

    phase 2 small molecule active

    1 trial

  29. ORX750

    Centessa Pharmaceuticals plc

    Narcolepsy Type 1

    phase 2 small molecule active

    2 trials

  30. ORX750, ORX750, ORX750, ORX750

    Centessa Pharmaceuticals plc

    Narcolepsy and Idiopathic Hypersomnia

    phase 2 small molecule active

    1 trial

  31. ORX750, ORX750, ORX750, Orx750 matching placebo, ORX750

    Centessa Pharmaceuticals plc

    Narcolepsy and Idiopathic Hypersomnia

    phase 2 small molecule active

    1 trial

  32. ORY-2001 Low dose

    BRIGHT MINDS BIOSCIENCES INC.

    Mild to Moderate Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  33. OSIMERTINIB MESYLATE, OSIMERTINIB MESYLATE, PEMBROLIZUMAB, BL-B01D1

    Bristol-Myers Squibb Australia Pty Ltd

    Advance solid tumors

    phase 2 small molecule active

    1 trial

  34. OT-101

    Oncotelic Therapeutics

    COVID-19

    phase 2 small molecule active

    1 trial

  35. OT-101

    Oncotelic Therapeutics

    Malignant Pleural Mesothelioma

    phase 2 small molecule active

    1 trial

  36. OVX836 480µg

    Harmony Biosciences Holdings

    Influenza

    phase 2 mab completed

    1 trial

  37. OVX836 shot

    Harmony Biosciences Holdings

    Vaccine-Preventable Diseases

    phase 2 mab completed

    1 trial

  38. OXALIPLATIN, AFLIBERCEPT, PANITUMUMAB, BEVACIZUMAB, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, IRINOTECAN, FLUOROURACIL, CETUXIMAB, AVELUMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY

    phase 2 small molecule active

    1 trial

  39. OXALIPLATIN, AZD0901, CAPECITABINE, FLUOROURACIL, AZD7789, volrustomig, CAPECITABINE, CALCIUM FOLINATE, Rilvegostomig

    AstraZeneca AB

    Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  40. OXALIPLATIN, CALCIUM FOLINATE, Quemliclustat, Zimberelimab, FLUOROURACIL, DOMVANALIMAB

    Arcus Biosciences

    Upper Gastrointestinal Tract Cancer, Advanced Upper Gastrointestinal Tract Malignancies, Gastrointestinal Tract Malignancies

    phase 2 small molecule active

    1 trial

  41. OXALIPLATIN, CISPLATIN, OXALIPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., PEMBROLIZUMAB, CAPECITABINE, TRASTUZUMAB, OXALIPLATIN, Rilvegostomig, CAPECITABINE, FLUOROURACIL, volrustomig, DS-8201a

    AstraZeneca AB

    Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressing gastric, GEJ and esophageal cancer

    phase 2 small molecule active

    1 trial

  42. OXALIPLATIN, ETOPOSIDE, CISPLATIN, CALCIUM FOLINATE, CAPECITABINE, IRINOTECAN, PACLITAXEL, FLUOROURACIL, TRABECTEDIN, DOCETAXEL, IFOSFAMIDE, PACLITAXEL ALBUMIN-BOUND, DOXORUBICIN, MITOTANE, CARBOPLATIN, GEMCITABINE

    Ningbo Cancer Hospital

    Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanced or metastatic cancer

    phase 2 small molecule active

    1 trial

  43. OXALIPLATIN, IRINOTECAN, Vectibix 20 mg/ml concentrate for solution for infusion, FOLINIC ACID, CALCIUM LEVOFOLINATE, FLUOROURACIL

    Ningbo Cancer Hospital

    RAS and B-RAF wild-type metastatic colorectal cancer. RAS and B-RAF mutation will be determined using circulating cell-free DNA (ccfDNA) by IntPlex method

    phase 2 small molecule active

    1 trial

  44. OXALIPLATIN, PANITUMUMAB, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, BEVACIZUMAB, NIVOLUMAB, TRASTUZUMAB

    Ningbo Cancer Hospital

    Patients with pMMR/MSS metastatic adenocarcinoma of the colon or rectum or gastroesophageal cancer (lower esophagus, gastroesophageal junction and gastric) and with known dihydropyrimidine dehydrogenase (DPD) deficiency defined as plasma uracil concentration ≥16 ng/ml, who undergo first-line treatment

    phase 2 small molecule active

    1 trial

  45. OZ439

    CNS Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

  46. Obatoclax

    Teva Pharma GmbH

    AML

    phase 2 small molecule completed

    1 trial

  47. Obatoclax

    Teva Pharma GmbH

    Extensive-stage Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  48. Obatoclax Mesylate

    Teva Pharma GmbH

    Metastatic Melanoma

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.